Clinical Trials

A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant

Protocol
07-035
Full Title
Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
Purpose

Patients with blood cancers that are not cured with a stem cell transplant do not have standard treatment options. Studies have shown that natural killer (NK) cells, a type of white blood cells, donated by another person can be given safely and may be helpful for treating some blood diseases. These NK cells are collected from the donor and purified before infusion into the patient.

In this study, researchers want to determine the effectiveness of giving NK cells to patients with leukemia or myelodysplastic syndrome (MDS) that has come back after a transplant and cannot be treated with a second transplant or with chemotherapy alone. They hope that giving chemotherapy and then NK cells will be a better treatment for these patients than currently available treatment options.

Investigator
Katharine C. Hsu, MD, PhD
Katharine C. Hsu - Physician Profile
Co-Investigators
James W. Young, MD -- Associate Chair, Department of Medicine
James W. Young - Physician Profile
Ann A. Jakubowski, MD, PhD -- Clinical Director, Adult Bone Marrow Transplantation Outpatient Unit
Ann A. Jakubowski - Physician Profile
Miguel-Angel Perales, MD -- Deputy Chief, Adult Bone Marrow Transplant Service; Director, Adult Bone Marrow Transplantation Fellowship Program
Miguel-Angel Perales - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of leukemia or MDS that has returned despite a prior transplant and cannot be cured with a second transplant or with chemotherapy alone.
  • Each patient must have a family member who shares 50 percent of the same HLA proteins (immune proteins important in blood transplant), has consented to donate NK cells to the patient, and is healthy enough to serve as a donor.
  • The patient’s original donor used for the prior transplant will need to agree to donate more stem cells. This is in case the patient’s bone marrow does not recover after the chemotherapy and the NK cell infusion.

For more information and to inquire about eligibility, please contact Dr. Katharine Hsu at 646-888-2667.

Disease(s)
Blood & Marrow Stem Cell Transplantation: Post-Transplant
Blood and Marrow Transplantation: Transplantation
Hematology: Myelodysplastic Syndrome
Leukemia
Leukemia: Myelodysplastic Syndrome
Locations
Related Diseases